Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy

Clinical and Experimental Allergy

Volumn 44, Issue 2, 2014, Pages 278-287

  Linhart, B ^a   Narayanan, M ^a   Focke Tejkl, M ^b   Wrba, F ^b   Vrtala, S ^a   Valenta, R ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergens; Allergy vaccination; Peptides; Specific immunotherapy

Indexed keywords

ALUMINUM HYDROXIDE; BLOCKING ANTIBODY; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE VACCINE; POLLEN ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BASOPHIL DEGRANULATION; BIRCH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PNEUMONIA; POLLEN ALLERGY; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE; VACCINATION;

ALLERGENS; ALLERGY VACCINATION; PEPTIDES; SPECIFIC IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, PLANT; BETULA; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED BALB C; PEPTIDES; RHINITIS, ALLERGIC, SEASONAL; VACCINATION; VACCINES;

EID: 84892707552     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12216     Document Type: Article

References (34)

1. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010; 40:385-97.
2. Katz DH, Paul WE, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization. J Exp Med 1970; 132:261-82.
3. Paul WE, Katz DH, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970; 132:283-99.
4. Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4.
5. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:2042-4.
6. Focke M, Linhart B, Hartl A et al. Non-anaphylactic, surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34:1525-33.
7. Edlmayr J, Niespodziana K, Linhart B et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182:6298-306.
8. Niespodziana K, Focke-Tejkl M, Linhart B et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-70.
9. Twaroch T, Focke M, Civaj V et al. Carrier-bound, non-allergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011; 128:178-84.
10. Chen KW, Focke-Tejkl M, Blatt K et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy 2012; 67:609-21.
11. Twaroch TE, Focke M, Fleischmann K et al. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy 2012; 42:966-75.
12. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012; 30:4328-35.
13. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
14. Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-41.
15. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208.
16. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101(Suppl 2):14677-82.
17. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-55.
18. van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-52.
19. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:313-8.
20. Breiteneder H, Pettenburger K, Bito A et al. The gene coding for the major birch pollen allergen Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 1989; 8:1935-8.
21. Niederberger V, Pauli G, Grönlund H et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998; 102:579-91.
22. Kazemi-Shirazi L, Pauli G, Purohit A et al. Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol 2000; 105:116-25.
23. Bauer L, Bohle B, Jahn-Schmid B et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107:536-41.
24. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-81.
25. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-7.
26. Vrtala S, Ball T, Spitzauer S et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998; 160:6137-44.
27. Linhart B, Bigenzahn S, Hartl A et al. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J. Immunol 2007; 178:3924-31.
28. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-60.
29. Hjelm F, Carlsson F, Getahun A, Heyman B. Antibody-mediated regulation of the immune response. Scand J Immunol 2006; 64:177-84.
30. Uthoff H, Spenner A, Reckelkamm W et al. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. J Immunol 2003; 1:3485-92.
31. Carlsson F, Hjelm F, Conrad DH, Heyman B. IgE enhances specific antibody and T-cell responses in mice overexpressing CD23. Scand J Immunol 2007; 66:261-70.
32. van der Heijden FL, van Neerven RJJ, van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993; 150:3643-50.
33. Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010; 40:1346-52.
34. Shamji MH, Francis JN, Würtzen PA, Lund K, Durham SR, Till SJ. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol 2013; 132:1003-5.